Figure 3 shows genes whose expression changed based on baricitinib’s inhibition of JAK1 and JAK2 signalling and the most significantly baricitinib-induced changed genes. Baricitinib altered the expression of genes involved in immune pathways, including multiple genes for key cytokines (STAT 1, 2 and 4), cytokine receptors, T cells, regulatory cells and cytokine regulators that are associated with the immune pathogenesis of SLE. This evidence concerns the gene JAK2 and systemic lupus erythematosus.